




RealRate

PHARMACEUTICAL 2019

Apellis Pharmaceuticals Inc.
Rank 244 of 371

Apellis



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Apellis Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Apellis Pharmaceuticals Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 316% points. The greatest weakness of Apellis Pharmaceuticals Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 409% points.

The company's Economic Capital Ratio, given in the ranking table, is -277%, being 54% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	202,439
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,025
Liabilities, Non-Current	0
Other Assets	1,094
Other Compr. Net Income	-123
Other Expenses	2,427
Other Liabilities	25,536
Other Net Income	-125,075
Property and Equipment	0
Research and Development	0
Revenues	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	203,534
Liabilities	42,561
Expenses	2,427
Stockholders Equity	160,973
Net Income	-127,502
Comprehensive Net Income	-127,564
Economic Capital Ratio	-277%